EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets

Weixiong Zhu, Chuanlei Fan, Yongqing Zhao, Youtao Liu, Yusheng Cheng, Wence Zhou

Hepatology International · 2025-08 · 19 (4) · 888-902

DOI: 10.1007/s12072-025-10799-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hepatology International, online erschienen am 29.03.2025. Verfasst von Weixiong Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, General project of traditional Chinese medicine in Gansu province, Gansu Provincial Top-notch Talent Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: To provide a reference for hepatocellular carcinoma (HCC) clinical trials, we analyzed HCC clinical trials and therapeutic targets. METHODS: Using the Informa database, we analyzed the global and China HCC clinical trials. We then explored TACE, Apatinib, and emerging strategies (CAR T/NK). Additionally, we analyzed the oncogenic biomarkers and therapeutic targets. We conducted a joint analysis of therapeutic target safety using HPA-RNA, HPA-Proteins, and GTEx-RNA datasets. Finally, we analyzed the specificity and prospects of therapeutic targets using HPA pathology data and CPTAC data. RESULTS: HCC clinical trials have developed rapidly over the past decade but have now reached a bottleneck, with most breakthroughs focusing on combination therapies. China and the USA dominate in the number of trials. TACE combined with systemic therapy has become an effective treatment strategy for intermediate to advanced HCC. Apatinib and TACE combined with systemic therapy are characteristic of China, while the latter is also mainly conducted in Japan and the USA. Currently, targeted immune therapies dominate the field, and CAR T/NK still in the early stages. Most therapeutic targets are related to the VEGF pathway, which indirectly confirms the predominant role of TKI-ICI combination therapy in HCC treatment. Most targets have low safety and poor specificity. However, RRM2, KDR, and AURKA have strong safety and specificity, showing excellent prospects for targeted HCC therapy. CONCLUSIONS: This study analyzed and summarized the overview of HCC clinical trials and the safety and specificity of therapeutic targets, providing a reference for HCC clinical research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansClinical Trials as TopicPyridinesMolecular Targeted TherapyChemoembolization, TherapeuticAntineoplastic AgentsBiomarkers, Tumor

Stichwörter der Autor:innen

Clinical trialsHepatocellular carcinomaImmunotherapyTACETargeted therapyTherapeutic target

Substanzen

PyridinesapatinibAntineoplastic AgentsBiomarkers, Tumor

Autor:innen und Institutionen

  • The Second Clinical Medical College, Lanzhou University, Lanzhou, China.
  • Department of Gastrointestinal Surgery, Jiangxi Province Hospital of Integrated Chinese and Western Medicine, Nanchang, Jiangxi, People's Republic of China.
  • School of Stomatology, Lanzhou University, Lanzhou, China.
  • Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, China. chengyusheng2017@163.com.
  • The Second Clinical Medical College, Lanzhou University, Lanzhou, China. zhouwc@lzu.edu.cn.
  • Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, China. zhouwc@lzu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • General project of traditional Chinese medicine in Gansu province
  • Gansu Provincial Top-notch Talent Program
  • Science and Technology Program of Gansu Province

Zitieren

APA

Zhu, W., Fan, C., Zhao, Y., Liu, Y., Cheng, Y., & Zhou, W. (2025). Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets. Hepatology International, 19(4), 888-902. https://doi.org/10.1007/s12072-025-10799-2

Vancouver

Zhu W, Fan C, Zhao Y, Liu Y, Cheng Y, Zhou W. Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets. Hepatology International. 2025;19(4):888-902. doi:10.1007/s12072-025-10799-2

BibTeX
@article{Zhu2025,
  author = {Zhu, Weixiong and Fan, Chuanlei and Zhao, Yongqing and Liu, Youtao and Cheng, Yusheng and Zhou, Wence},
  title = {Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets},
  journal = {Hepatology International},
  year = {2025},
  volume = {19},
  number = {4},
  pages = {888--902},
  doi = {10.1007/s12072-025-10799-2}
}
Kostenlos starten →